Anatomical Therapeutic Chemical • L01FX04 • ipilimumab

A Alimentary tract and metabolism

B Blood and blood forming organs

C Cardiovascular system

D Dermatologicals

G Genito urinary system and sex hormones

H Systemic hormonal preparations, excluding sex hormones and insulins

J Antiinfectives for systemic use

L Antineoplastic and immunomodulating agents

L01 Antineoplastic agents

L01A Alkylating agents

L01B Antimetabolites

L01C Plant alkaloids and other natural products

L01D Cytotoxic antibiotics and related substances

L01E Protein kinase inhibitors

L01F Monoclonal antibodies and antibody drug conjugates

L01FA Cd20 (clusters of differentiation 20) inhibitors

L01FB Cd22 (clusters of differentiation 22) inhibitors

L01FC Cd38 (clusters of differentiation 38) inhibitors

L01FD Her2 (human epidermal growth factor receptor 2) inhibitors

L01FE Egfr (epidermal growth factor receptor) inhibitors

L01FF Pd-1/pdl-1 (programmed cell death protein 1/death ligand 1) inhibitors

L01FG Vegf/vegfr (vascular endothelial growth factor) inhibitors

L01FX Other monoclonal antibodies and antibody drug conjugates

L01FX02 gemtuzumab ozogamicin Indicated for: cancer

L01FX03 catumaxomab Indicated for: malignant ascites

L01FX04 ipilimumab Indicated for: cancer

L01FX09 mogamulizumab Indicated for: cancer

L01FX12 tafasitamab Indicated for: hematologic malignancies

L01FX13 enfortumab vedotin Indicated for: urothelial cancer

L01FX14 polatuzumab vedotin Indicated for: cancer

L01FX17 sacituzumab govitecan Indicated for: breast cancer

L01FX18 amivantamab Indicated for: non-small cell lung cancer

L01FX20 tremelimumab Indicated for: cancer; oncologic immunotherapy

L01FX22 loncastuximab tesirin Indicated for: cancer

L01FX24 teclistamab Indicated for: multiple myeloma

L01FX25 mosunetuzumab Indicated for: lymphoma

L01FX26 mirvetuximab soravtansin Indicated for: ovarian cancer

L01FX27 epcoritamab Indicated for: hematologic malignancies

L01FX28 glofitamab Indicated for: hematologic malignancies

L01FX29 talquetamab Indicated for: hematologic malignancies

L01FX31 zolbetuximab Indicated for: cancer

L01FX32 elranatamab Indicated for: hematologic malignancies

L01FX33 tarlatamab Indicated for: extensive-stage small cell lung cancer after platinum-based chemotherapy

L01FY Combinations of monoclonal antibodies and antibody drug conjugates

L01X Other antineoplastic agents

L02 Endocrine therapy

L03 Immunostimulants

L04 Immunosuppressants

M Musculo-skeletal system

N Nervous system

P Antiparasitic products, insecticides and repellents

R Respiratory system

S Sensory organs

V Various